Hikma And GSK Will Not Move Ahead With MENA Deal

Potential Transaction Would Have Seen Hikma Acquire Businesses In Egypt And Tunisia

Hikma and GSK have agreed not to proceed with a deal being explored by the two firms that would have seen Hikma acquire a majority stake in the firm’s pharmaceutical and consumer health business in Egypt and Tunisia.

Broken handshake
Hikma and GSK have decided not to proceed with their deal • Source: Shutterstock

Hikma and GlaxoSmithKline have decided not to proceed with a deal that would have seen Hikma acquire a majority stake in the firm’s pharmaceutical and consumer health business in Egypt and Tunisia, the companies have announced.

In January, Hikma revealed that it had entered a non-binding term sheet for GSK’s pharmaceutical and consumer businesses in Egypt...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

Nexus Faces Five Year Wait On Injectable Minocycline

Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains

test

uygukgigo

 
• By 

More from Business

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success - C8

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

UK Invests £28m In NHS AI, But Industry Says Procurement And Training Will Determine Success

 
• By 

The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda - Clone - Clone

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains